OraSure Technologies, Inc.
OSURHealthcareNASDAQMedical Instruments & Supplies · Last scanned Sep 8, 2026
Scan Results
Daily timeframeOraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe,. The company carries a $240.0M market cap, placing it firmly in the micro-cap category. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
Market Cap
$240.0M
Beta
0.99
P/E (TTM)
—
P/E (Fwd)
-5.27
EPS (TTM)
$-0.69
EPS (Fwd)
$-0.66
ROE
-14.1%
ROA
-11.0%
Cash
$160.6M
Total Debt
$12.1M
Free CF
-$44.6M
52W Change
3.9%
Annual Financials
Cash vs Debt
Where OSUR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, OSUR finished 3.44% above its 150-day moving average ($3.49) and 11.42% above its 200-day moving average ($3.24). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OSUR overbought or oversold?
At the September 3, 2026 close, OSUR's RSI(14) was 28.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $160.6M in cash and $12.1M in debt, OSUR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$44.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -14.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $387.5M (2022) to $115.0M (2025), a 70% decline worth watching.
With cash comfortably exceeding debt, OSUR has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing OSUR.